Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
11 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Sagimet Biosciences Inc.’s names, not what it holds today.
Patents granted
11
11 utility, 1976 to Dec 31, 2025
Granted in 2025
none
Against none in 2024 and 1 in 2023
Applications published
21
2 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'14'15'16'17'18'19'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
3-V Biosciences, Inc. a former name
US, as the owner printed on each patent
5 published3-V Biosciences, Inc. a former name
named as the applicant on its applications, in US
10 publishedSagimet Biosciences Inc. its own name
named as the applicant on its applications, in US
6 publishedSagimet Biosciences Inc. its own name
US, as the owner printed on each patent
0 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Apr 11, 2023 | 11,622,968 | Heterocyclic modulators of lipid synthesis | Organic fine chemistry | Sagimet Biosciences Inc. |
| Jul 30, 2019 | 10,363,249 | Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer | Pharmaceuticals | 3-V Biosciences, Inc. |
| Mar 12, 2019 | 10,226,449 | Heterocyclic modulators of lipid synthesis and combinations thereof | Pharmaceuticals | 3-V Biosciences, Inc. |
| Jan 29, 2019 | 10,189,822 | Heterocyclic modulators of lipid synthesis | Pharmaceuticals | 3-V Biosciences, Inc. |
| Nov 6, 2018 | 10,118,913 | Heterocyclic modulators of lipid synthesis | Organic fine chemistry | 3-V Biosciences, Inc. |
| Aug 21, 2018 | 10,053,450 | Heterocyclic modulators of lipid synthesis | Organic fine chemistry | 3-V Biosciences, Inc. |
| Jun 12, 2018 | 9,994,550 | Heterocyclic modulators of lipid synthesis for use against cancer and viral infections | Pharmaceuticals | 3-V Biosciences, Inc. |
| Nov 7, 2017 | 9,809,591 | Heterocyclic modulators of lipid synthesis | Organic fine chemistry | 3-V Biosciences, Inc. |
| Apr 18, 2017 | 9,624,173 | Heterocyclic modulators of lipid synthesis | Organic fine chemistry | 3-V Biosciences, Inc. |
| Aug 30, 2016 | 9,428,502 | Heterocyclic modulators of lipid synthesis | Organic fine chemistry | 3-V Biosciences, Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| May 22, 2025 | 2025/0166821 | METHODS FOR PREDICTION OF TREATMENT RESPONSE IN NON-ALCOHOLIC FATTY LIVER DISEASE | Medical technology | Sagimet Biosciences Inc. |
| Jan 16, 2025 | 2025/0017938 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | Pharmaceuticals | Sagimet Biosciences Inc. |
| Dec 5, 2024 | 2024/0400552 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Organic fine chemistry | Sagimet Biosciences Inc. |
| Dec 21, 2023 | 2023/0405016 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Organic fine chemistry | Sagimet Biosciences Inc. |
| Oct 27, 2022 | 2022/0340556 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Organic fine chemistry | Sagimet Biosciences Inc. |
| Sep 22, 2022 | 2022/0296605 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Organic fine chemistry | Sagimet Biosciences Inc. · patent 11,622,968 granted from it |
| Oct 10, 2019 | 2019/0308969 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Pharmaceuticals | 3-V Biosciences, Inc. · patent 11,034,690 granted from it |
| Sep 5, 2019 | 2019/0269694 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Organic fine chemistry | 3-V Biosciences, Inc. |
| Aug 9, 2018 | 2018/0222892 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Organic fine chemistry | 3-V Biosciences, Inc. · patent 10,118,913 granted from it |
| Mar 22, 2018 | 2018/0079746 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | Pharmaceuticals | 3-V Biosciences, Inc. · patent 10,189,822 granted from it |
What it applied for, 2024 to 2025: Organic fine chemistry 1 · Pharmaceuticals 1 · Medical technology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.